The DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Open accessAbstract
Background & aims Agents that induce an immune response against tumors by altering T-cell regulation have increased survival times of patients with advanced-stage tumors, such as melanoma or lung cancer. We aimed to characterize molecular features of immune cells that infiltrate hepatocellular carcinomas (HCCs) to determine whether these types of agents might be effective against liver tumors.Methods We analyzed HCC samples from 956 patients. We separated gene expression profiles from tumor, stromal, and immune cells using a non-negative matrix factorization algorithm. We then analyzed the gene expression pattern of inflammatory cells in HCC tumor samples. We correlated expression patterns with the presence of immune cell infiltrates and immune regulatory molecules, determined by pathology and immunohistochemical analyses, in a training set of 228 HCC samples. We validated the correlation in a validation set of 728 tumor samples. Using data from 190 tumors in the Cancer Genome Atlas, we correlated immune cell gene expression profiles with numbers of chromosomal aberrations (based on single-nucleotide polymorphism array) and mutations (exome sequence data).Results We found approximately 25% of HCCs to have markers of an inflammatory response, with high expression levels of the CD274 molecule (programmed death-ligand 1) and programmed cell death 1, markers of cytolytic activity, and fewer chromosomal aberrations. We called this group of tumors the Immune class. It contained 2 subtypes, characterized by markers of an adaptive T-cell response or exhausted immune response. The exhausted immune response subclass expressed many genes regulated by transforming growth factor beta 1 that mediate immunosuppression. We did not observe any differences in numbers of mutations or expression of tumor antigens between the immune-specific class and other HCCs.Conclusions In an analysis of HCC samples from 956 patients, we found almost 25% to express markers of an inflammatory response. We identified 2 subclasses, characterized by adaptive or exhausted immune responses. These findings indicate that some HCCs might be susceptible to therapeutic agents designed to block the regulatory pathways in T cells, such as programmed death-ligand 1, programmed cell death 1, or transforming growth factor beta 1 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Inflamed tumours constitute ~30% of HCCs and exhibit extensive immune cell infiltration and immune activity, detected as increased expression of immune checkpoints (such as PD-1 or its ligand PD-L1), activation of IFN signalling and a low burden of large chromosomal alterations70,71,78.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [71]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, a high TMB does not correlate with increased immune infiltration70,71.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Murray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Cho, E. J., Kim, M., Jo, D., Kim, J., Oh, J.-H., Chung, H. C., Lee, S.-H., Kim, D., Chun, S.-M., Kim, J., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14978127
Liu, L., Wang, Q., Wu, L., Zhang, L., Huang, Y., Yang, H., guo, L., Fang, Z., & Wang, X. (2023) · Figshare · doi:10.6084/m9.figshare.23689656
Cho, E. J., Kim, M., Jo, D., Kim, J., Oh, J.-H., Chung, H. C., Lee, S.-H., Kim, D., Chun, S.-M., Kim, J., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14978103
Ma, C., Yang, C., Peng, A., Sun, T., Ji, X., Mi, J., Wei, L., Shen, S., & Feng, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26626627
Ma, C., Yang, C., Peng, A., Sun, T., Ji, X., Mi, J., Wei, L., Shen, S., & Feng, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26626654
Shi, A., Yan, M., Pang, B., Pang, L., Wang, Y., Lan, Y., Zhang, X., Xu, J., Ping, Y., & Hu, J. (2024) · Figshare · doi:10.6084/m9.figshare.26652312
Ma, C., Yang, C., Peng, A., Sun, T., Ji, X., Mi, J., Wei, L., Shen, S., & Feng, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26626609
Ma, C., Yang, C., Peng, A., Sun, T., Ji, X., Mi, J., Wei, L., Shen, S., & Feng, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26626573
Zhu, H.-F., Feng, J.-K., Xiang, Y.-J., Wang, K., Zhou, L.-P., Liu, Z., Cheng, Y.-Q., Shi, J., Guo, W.-X., & Cheng, S.-Q. (2023) · Figshare · doi:10.6084/m9.figshare.23529061
Ma, C., Yang, C., Peng, A., Sun, T., Ji, X., Mi, J., Wei, L., Shen, S., & Feng, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26626588
Ma, C., Yang, C., Peng, A., Sun, T., Ji, X., Mi, J., Wei, L., Shen, S., & Feng, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26626612
Zhu, H.-F., Feng, J.-K., Xiang, Y.-J., Wang, K., Zhou, L.-P., Liu, Z.-H., Cheng, Y.-Q., Shi, J., Guo, W.-X., & Cheng, S.-Q. (2023) · Figshare · doi:10.6084/m9.figshare.23529070
Ma, C., Yang, C., Peng, A., Sun, T., Ji, X., Mi, J., Wei, L., Shen, S., & Feng, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26626624
Cho, E. J., Kim, M., Jo, D., Kim, J., Oh, J.-H., Chung, H. C., Lee, S.-H., Kim, D., Chun, S.-M., Kim, J., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14978142
Xu, Y., Zhang, Z., Xu, D., Yang, X., Zhou, L., & Zhu, Y. (2021) · Figshare · doi:10.6084/m9.figshare.15102697
Ortiz-Barahona, V., Soler, M., Dávalos, V., García-Prieto, C. A., Janin, M., Setién, F., Fernández-Rebollo, I., Bech‐Serra, J. J., de la Torre, C., Guil, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22814993
Self-citationZheng, Q., Yang, Q., Zhou, J., Gu, X., Zhou, H., Dong, X., Zhu, H., & Chen, Z. (2021) · Figshare · doi:10.6084/m9.figshare.14889916
Cho, E. J., Kim, M., Jo, D., Kim, J., Oh, J.-H., Chung, H. C., Lee, S.-H., Kim, D., Chun, S.-M., Kim, J., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14978106
Cho, E. J., Kim, M., Jo, D., Kim, J., Oh, J.-H., Chung, H. C., Lee, S.-H., Kim, D., Chun, S.-M., Kim, J., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14978130
Cho, E. J., Kim, M., Jo, D., Kim, J., Oh, J.-H., Chung, H. C., Lee, S.-H., Kim, D., Chun, S.-M., Kim, J., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14978133
Xu, Y., Zhang, Z., Xu, D., Yang, X., Zhou, L., & Zhu, Y. (2021) · Figshare · doi:10.6084/m9.figshare.15102700
Cho, E. J., Kim, M., Jo, D., Kim, J., Oh, J.-H., Chung, H. C., Lee, S.-H., Kim, D., Chun, S.-M., Kim, J., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14978118
Xu, Y., Zhang, Z., Xu, D., Yang, X., Zhou, L., & Zhu, Y. (2021) · Figshare · doi:10.6084/m9.figshare.15102715
Zhu, H.-F., Feng, J.-K., Xiang, Y.-J., Wang, K., Zhou, L.-P., Liu, Z.-H., Cheng, Y.-Q., Shi, J., Guo, W.-X., & Cheng, S.-Q. (2023) · Figshare · doi:10.6084/m9.figshare.23529067
Ma, C., Yang, C., Peng, A., Sun, T., Ji, X., Mi, J., Wei, L., Shen, S., & Feng, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26626648
Ma, C., Yang, C., Peng, A., Sun, T., Ji, X., Mi, J., Wei, L., Shen, S., & Feng, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26626651
Ortiz-Barahona, V., Soler, M., Dávalos, V., García-Prieto, C. A., Janin, M., Setién, F., Fernández-Rebollo, I., Bech‐Serra, J. J., de la Torre, C., Guil, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22814999
Self-citationXu, Y., Zhang, Z., Xu, D., Yang, X., Zhou, L., & Zhu, Y. (2021) · Figshare · doi:10.6084/m9.figshare.15102682
Hu, Y., Liu, J., Yu, J., Yang, F., Zhang, M., Liu, Y., Ma, S., Zhou, X., Wang, J., & Han, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19219140
Cho, E. J., Kim, M., Jo, D., Kim, J., Oh, J.-H., Chung, H. C., Lee, S.-H., Kim, D., Chun, S.-M., Kim, J., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14978112
Gu, X., Guan, J., Xu, J., Zheng, Q., Chen, C., Yang, Q., Huang, C., Wang, G., Zhou, H., Chen, Z., et al. (2021) · Figshare · doi:10.6084/m9.figshare.13531693
Ma, C., Yang, C., Peng, A., Sun, T., Ji, X., Mi, J., Wei, L., Shen, S., & Feng, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26626621
Ma, C., Yang, C., Peng, A., Sun, T., Ji, X., Mi, J., Wei, L., Shen, S., & Feng, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26626585
Ma, C., Yang, C., Peng, A., Sun, T., Ji, X., Mi, J., Wei, L., Shen, S., & Feng, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26626633
Ortiz-Barahona, V., Soler, M., Dávalos, V., García-Prieto, C. A., Janin, M., Setién, F., Fernández-Rebollo, I., Bech‐Serra, J. J., de la Torre, C., Guil, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22814987
Self-citationOrtiz-Barahona, V., Soler, M., Dávalos, V., García-Prieto, C. A., Janin, M., Setién, F., Fernández-Rebollo, I., Bech‐Serra, J. J., de la Torre, C., Guil, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22815005
Self-citationCho, E. J., Kim, M., Jo, D., Kim, J., Oh, J.-H., Chung, H. C., Lee, S.-H., Kim, D., Chun, S.-M., Kim, J., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14978109
Xu, Y., Zhang, Z., Xu, D., Yang, X., Zhou, L., & Zhu, Y. (2021) · Figshare · doi:10.6084/m9.figshare.15102712
Zhu, H.-F., Feng, J.-K., Xiang, Y.-J., Wang, K., Zhou, L.-P., Liu, Z.-H., Cheng, Y.-Q., Shi, J., Guo, W.-X., & Cheng, S.-Q. (2023) · Figshare · doi:10.6084/m9.figshare.23529076
Li, C., Li, X., Niu, M., Xiao, D., Luo, Y., Wang, Y., Fang, Z.-E., Zhan, X., Zhao, X., Fang, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.27129452
Ma, C., Yang, C., Peng, A., Sun, T., Ji, X., Mi, J., Wei, L., Shen, S., & Feng, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26626582
Ayhan, M., Dogan, A., Keser, S. H., Başak, K., Akdeniz, N., Atçı, M. M., Erhan, S. Ş., ARIKAN, R., Çelikel, Ç., Turan, N., et al. (2026) · Journal of International Medical Research · doi:10.1177/03000605251386599
191Chapter 9 Leveraging AI for liver cancer diagnosis and treatment
Malviya, R., Rajput, S., Roy, M., Sridhar, S. B., & Thomas, S. (2025) · De Gruyter eBooks · doi:10.1515/9783111670744-009
Ogasawara, S., Koroki, K., Makishima, H., Masaru, W., Takahashi, A., Fujiya, M., Yumita, S., Nakagawa, M., Kanzaki, H., Kobayashi, K., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101765
Zhong, D., Liang, Y., Su, Y., Yang, Q., Yan, H., Shi, Y., Huang, X., & Shang, J. (2026) · Technology in Cancer Research & Treatment · doi:10.1177/15330338261421357
Šafčák, D., Dražilová, S., Gazda, J., Selčanová, S. A., Balážová, L., Barila, R., Комарова, С. Г., Mego, M., Rác, M., Skladaný, Ľ., et al. (2026) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-026-00530-4
Williams, C. M., Calderon, J. H., DiBlasi, V. R., Liu, L. J., Nuwayhid, S. J., Cevasco, H., Wang, W., Soni, R., Adler, C., D’Ambrosio, D. W., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-40894-9
Integrated analysis and clinical impact of immune and stromal microenvironments in solid tumors
Petitprez, F. (2018) · theses.fr (ABES) · doi:10.70675/cea357bazafbaz4eaaz94e5zc5f644de5018
Alteration of alternative splicing in the pathogenesis of liver disease
Wang, H. (2017) · theses.fr (ABES) · doi:10.70675/bbd0da03z44bcz4adczaedazc17212ba6ebe
Mécanismes d'immunosurveillance NKG2D et DNAM-1 dans le carcinome hépatocellulaire
Cadoux, M. (2019) · theses.fr (ABES) · doi:10.70675/a6660468zb747z4a0czb963z900d06687ec7
Développement d'une stratégie Cheval de Troie dans le traitement du carcinome hépatocellulaire
Nayagom, B. (2019) · theses.fr (ABES) · doi:10.70675/780d49f6zde47z4ff1z9bc4z7e014070104c
Farés, N. (2019) · theses.fr (ABES) · doi:10.70675/eef9404azffadz4212z9948z699104f7c1ab
Hobeika, C. (2022) · theses.fr (ABES) · doi:10.70675/4c247323z584fz42b6za12cze7812b01da9e
Rôle de LECT2 dans les maladies stéatosiques non alcooliques du foie
Pham, S. (2020) · theses.fr (ABES) · doi:10.70675/3693bfe6z9d91z4045za9a9zc37497dc9c1b
Rôle et pertinence clinique du facteur de transcription FOXS1 dans le carcinome hépatocellulaire
Bévant, K. (2021) · theses.fr (ABES) · doi:10.70675/f8cfc7baz9aeez4eb6zbcc6z7e9c846533f8
Rôle de Programmed cell Death-Ligand 1 dans la progression du carcinome hépatocellulaire
Rousseau, B. (2021) · theses.fr (ABES) · doi:10.70675/dd181429zd664z4681zbe04z06271b5e1f39
Deng, Z., Li, Y., Shen, Y., & Zhou, M. (2026) · International Journal of Genomics · doi:10.1155/ijog/9720283
Rôle de l'isoforme A du récepteur de l'insuline dans l'homéostasie et la carcinogenèse hépatiques
Léandre, F. (2024) · theses.fr (ABES) · doi:10.70675/df1bc445z5d98z462dzbc59za0d4015bcf04
Fascin-1 as a druggable target in Hepatoblastoma
Dif, L. (2024) · theses.fr (ABES) · doi:10.70675/397187b4z98e4z4886zb816z1a59af68ea71
Connor, A., Mattohti, M., Kodali, S., Abdelrahim, M., Elaileh, A., Semaan, S., Dib, Y., Patel, K., Todd, J., Sengupta, U., et al. (2026) · Frontiers in Transplantation · doi:10.3389/frtra.2026.1758576
Self-citationSheng, X., & Qin, J.-M. (2026) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v34.i3.190
Renewed momentum for HCV and HCC research
Kinast, V., Désert, R., Bartenschlager, R. F. W., Baumert, T. F., & Steinmann, E. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.03.033
Tameshkel, F. S., Kalaki, N. S., Karimi, E., Razizadeh, M. H., Haidar, A. E. H., Amiri, A., Zaki, M., Nikkhah, M., & Niya, M. H. K. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201218
Next-Generation Sequencing in Hepatobiliary Carcinomas
Sioletic, S., & Baiocchini, A. (2026) · Current clinical pathology · doi:10.1007/978-3-032-18790-1_5
Piñero, F., Chan, S. L., & Vogel, A. (2026) · Annals of Hepatology · doi:10.1016/j.aohep.2026.102235
Wu, S., Peng, F., Huang, J., Xu, L., Zhang, X., Bao, Y., & Chen, Y. (2026) · European Radiology Experimental · doi:10.1186/s41747-026-00730-1
O’Rourke, J. M., Kavanagh, D., O'Keeffe, A., Savoye, K., Yang, K., Patten, D. A., Willoughby, C. E., Llovet, J. M., Neag, G., Reeves, H. L., et al. (2026) · The Journal of Pathology · doi:10.1002/path.70077
Self-citationTang, S., Cai, H., Wu, Z. Z., Huang, S., Zhao, L., Wu, L., Gong, L., & Guo, W. (2026) · BMC Cancer · doi:10.1186/s12885-026-16286-7
Väyrynen, V., Eloranta, K., Talka, M., Tuhkala, A., Lohi, J., Varjosalo, M. T., Kyrönlahti, A., Jalkanen, S., Hollmén, M., Pihlajoki, M., et al. (2026) · American Journal Of Pathology · doi:10.1016/j.ajpath.2026.05.006
Fu, Z., Zhang, Y., Wang, Z., Li, Z., & Du, S. (2026) · Precision Radiation Oncology · doi:10.1002/pro6.70057
Kimura, M., Nishikawa, K., Imamura, J., & Kimura, K. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04487-9
Yuza, K., & Pawlik, T. M. (2026) · Cancers · doi:10.3390/cancers18142234
Jiang, W.-Y., Feng, J.-K., Zhang, Y., Zhang, J.-D., Hu, X.-Q., Cheng, S., & Zhang, T.-S. (2026) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2026.07.011
Zhang, L., Zhang, X., Liu, C., Xin, X., Luan, X., Song, J., & Qiu, W. (2026) · Discover Oncology · doi:10.1007/s12672-026-05700-y
Iwasaki, H., Itoh, S., Toshida, K., Mita, J., Ishikawa, T., Iseda, N., Yugawa, K., Yoshiya, S., Motomura, T., Toshima, T., et al. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000001014
Dang, Z., Dan, J., Su, W., Ren, G., Wang, Z., Ma, Y., Li, S., Ji, D., Li, L., Gao, J., et al. (2026) · medRxiv · doi:10.64898/2026.08.08.26360002
Qin, L., Zhu, L., Yang, H., Li, W., Zhang, S., Shen, J., & Zhu, X. (2026) · Clinical & Translational Immunology · doi:10.1002/cti2.70115
An, J., Kim, W., Zhang, X., Chikontwe, P., Ju, J., Oh, B., Oh, J., Yang, E. J., Namgung, H., Lee, D., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02815-0
Yuza, K., Kawashima, J., Akabane, M., & Pawlik, T. M. (2026) · Cancers · doi:10.3390/cancers18162696
Han, G., Mi, L., Shi, J., Wang, J., & Yin, F. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1851314
Neupane, A., Budhu, A., Mehrabadi, F. R., 何爱武, Goyal, L., Kelley, R. K., Greten, T. F., & Wang, X. W. (2026) · eGastroenterology · doi:10.1136/egastro-2026-100423
Tang, Y., Liu, K.-J., Tan, Z., & Zhao, W. (2026) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl53642
An, P., Wu, L., & Wang, R. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119883
Zhang, E., Ma, P., Zhao, W.-J., & Du, J.-J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1782572
Neely, J., Yao, J. J., Kudo, M., Finn, R. S., Sangro, B., Melero, I., El-Khoueiry, A. B., Yau, T. C. C., Harding, J. J., Rosmorduc, O., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.102038
Modeling Liver Cancer Molecular and Histological Features by CRISPR Editing of Porcine Hepatocytes
Elkhadragy, L., David, O. G., Castillo, C. C., Redlon, L. N., Jordan, L. R., Khan, N., Liu, H., Lopes, I. A. R., Zhou, Y., Kanzaki, H., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.102042
The Rationale for Tissue Biopsy in the Era of Precision Hepatocellular Carcinoma Management
Grypari, I. M., Tiniakos, D. G., Kalafateli, M., & Theocharidou, E. (2026) · Cancers · doi:10.3390/cancers18193115
Fu, X., Guo, Y., Gong, B., Lou, J., Wang, N., Chen, X., Hu, H.-T., Wang, R., Guo, X., Shanmei, L., et al. (2026) · Advanced Science · doi:10.1002/advs.78005
Lin, L., Weng, N., Lai, H., Wu, G., Lin, J., Wu, X., Huang, S., & Chen, X. (2026) · PLoS ONE · doi:10.1371/journal.pone.0359327
Law, J. H., Xie, K., Yang, J., Kudo, M., Muthiah, M., Mehta, N. J., Bhoori, S., Pinato, D. J., Chee, C. E., Hatano, E., et al. (2026) · Liver Cancer · doi:10.1159/lic/admag012
Self-citationHu, D., & Wang, Q. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1959317
Jiao, J., & Zhang, X. (2026) · Human Pathology · doi:10.1016/j.humpath.2026.106275
Tan, Y., Xu, S., 刘小方, Liao, W.-W., Zhu, R., Shen, M., Wang, W., Liu, M., & Liu, J. (2026) · Abdominal Radiology · doi:10.1007/s00261-026-05788-4
Transcriptomic analysis reveals AURKB promotes malignant progression of hepatocellular carcinoma
Sun, W., Sihua, L., Zhang, D., Yang, S., Wang, D., Zhou, S., Liu, Z., Lu, Z., & Wang, Y. (2026) · Acta Histochemica · doi:10.1016/j.acthis.2026.152357
Yang, W., Hanyu, J., Liu, C., Wei, J., Zhou, Y., Gong, P., Song, B., & Jie, T. (2021) · Chinese Medical Sciences Journal · doi:10.1016/s1001-9294(21)00055-9 · Cited by 5
Chen, Y., Peng, T., Nie, H., & Hu, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1944650
Metadata
- Authors
- Sia, D., Jiao, Y., Martinez-Quetglas, I., Kuchuk, O., Villacorta-Martin, C., Castro de Moura, M., Putra, J., Camprecios, G., Bassaganyas, L., Akers, N., Losic, B., Waxman, S., Thung, S. N., Mazzaferro, V., Esteller, M., Friedman, S. L., Schwartz, M., Villanueva, A., & Llovet, J. M.
- Affiliations
- Tisch Cancer Institute (US)
- Hospital Clínic de Barcelona (ES)
- University of Milan (IT)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Llovet, Josep M.
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 153
- Issue
- 3
- Pages
- 812-826
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC12166766
- OpenAlex
- W2626033245
- Cited by
- 976
- References
- 46
- Citations by year
- 2026: 65 · 2025: 82 · 2024: 124 · 2023: 136 · 2022: 155 · 2021: 188 · 2020: 104 · 2019: 72 · 2018: 41 · 2017: 9
- FWCI
- 27.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Gastroenterology (acceptedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (acceptedVersion, cc-by-nc-nd)
- Funders
- Tisch Cancer Institute (P30 CA196521)
- US Department of Defense (CA150272P3)
- European Commission Framework Program 7 (259744)
- Horizon 2020 Program (667273–2)
- Asociación Española Contra el Cáncer
- Samuel Waxman Cancer Research Foundation
- Spanish National Health Institute (SAF2013–41027)
- Grup de Recerca Consolidat–Recerca Translacional en Oncologia Hepàtica
- AGAUR (SGR 1162)
- European Commission HEPCAR
- Onlus Prometeo
- Hepato-Oncology Research Project
- Istituto Nazionale Tumori
- National Cancer Institute
- IRCCS Foundation
- Juan de la Cierva Fellowship
- Associazione Italiana per la Ricerca sul Cancro
- Italian Ministry of Health
- National Institutes of Health (R01DK56621)
- American Association
- Liver Diseases Foundation Alan Hofmann Clinical and Translational Award
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- hepatocellular carcinoma, tumor immune microenvironment, immune cell infiltration, PD-1, T cell exhaustion, TGF-β1, chromosomal abnormalities, cancer mutations, tumor-infiltrating immune cells, immune checkpoint inhibitors, tumor subtypes, gene expression profiling, non-negative matrix factorization, tides
- MeSH terms
- Aged, Female, Carcinoma, Hepatocellular, Humans, Immune Tolerance, Immunohistochemistry, Liver Neoplasms, Male, Middle Aged, Mutation, Signal Transduction, Gene Expression Regulation, Neoplastic, Immunophenotyping, Lymphocytes, Tumor-Infiltrating, DNA Methylation, beta Catenin, Transforming Growth Factor beta1, Adaptive Immunity, Tumor Microenvironment, Transcriptome, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
